WASHINGTON,D.C FORM8-K. CurrentReport PursuanttoSection13or15(d)ofthe

Size: px

Start display at page:

Download "WASHINGTON,D.C FORM8-K. CurrentReport PursuanttoSection13or15(d)ofthe"

Pauline York
5 years ago
Views:

1 UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION WASHINGTON,D.C FORM8-K CurrentReport PursuanttoSection13or15(d)ofthe SecuritiesExchangeActof1934 April3,2017 DateofReport(DateofEarliestEventReported) IntelGenxTechnologiesCorp. (ExactNameofRegistrantasSpecifiedinitsCharter) Delaware (Stateorotherjurisdictionof (CommissionFile (IRSEmployerIdentification incorporation) Number) No.) 6420Abrams,VilleSt-Laurent,Quebec,Canada (Addressofprincipalexecutiveoffices) H4S1Y2 (ZipCode) Registrant'stelephonenumber,includingareacode:(514) Check the appropriate box below if the Form 8K fining is intended to simultaneously satisfy the filing obligation of the registrant under anyofthefollowing provisions: []WrittencommunicationspursuanttoRule425undertheSecuritiesAct(17CFR ) []SolicitingmaterialpursuanttoRule14a-12undertheExchangeAct(17CFR240.14a-12) []Pre-commencementcommunicationspursuanttoRule14d-2(b)undertheExchangeAct(17CFR240.14d-2(b)) []Pre-commencementcommunicationpursuanttoRule13e-4(c)undertheExchangeAct(17CFR240.13e-4(c))

2 Item8.01OtherEvents-NewsRelease IntelGenx and Tetra Bio-Pharma Announce the Signing of a Definitive Agreement for the Development and Commercialization of a Dronabinol XL Tablet Exhibit Description 99.1 PressRelease SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by theundersigned hereuntodulyauthorized. INTELGENXTECHNOLOGIESCORP. Dated:April3,2017 By: /s/horstg.zerbe HorstG.Zerbe PresidentandChiefExecutiveOfficer

3 IntelGenx and Tetra Bio-Pharma Announce the Signing of a Definitive Agreement for the Development and Commercialization of a Dronabinol XL Tablet SAINTLAURENT,QUEBEC-(April3,2017) IntelGenxCorp.( IntelGenx )(TSXV:IGX)(OTCQX:IGXT)andTetraBio-PharmaInc.( Tetra )(CSE: TBP)(OTCPINK:GRPOF),todayannouncedthesigningofadefinitiveagreementforthedevelopmentandcommercializationofadrugproductcontainingthe cannabinoiddronabinol(the Product )forthemanagementofanorexiaandcancerchemotherapy-relatedpain.thisdefinitiveagreementfollowsthebindingterm sheetbetweenthetwocompaniesthatwasannouncedonfebruary9,2017. Pursuanttothedefinitiveagreement,TetrahasexclusiverightstoselltheProductinNorthAmerica,witharightoffirstnegotiationforterritoriesoutsideofthe UnitedStatesandCanada.TetrawillmakeanupfrontpaymenttoIntelGenx,inadditiontosetfuturemilestoneandroyaltypayments,basedonthecompletionof anefficacystudy,approvalsfromtheu.s.foodanddrugassociation( FDA )andhealthcanada,andthecommerciallaunchoftheproduct.intelgenxwillbe responsiblefortheresearchanddevelopmentoftheproduct,includingclinicalstudies,andwilldeveloptheproductasanoralmucoadhesivetabletbasedonits proprietaryadversa controlled-release technology. Tetra will be responsible for funding the product development, and will own and control all regulatory approvals,includingtherelatedapplications,andanyothermarketingauthorizations.tetrawillalsoberesponsibleforallaspectsofcommercializingtheproduct. TheU.S.cancerpainmarketisexpectedtoreach$5billionin2018,andthequickgrowingmedicalcannabisindustryispoisedtocaptureasignatureportionof thatopportunity, saiddr.horstg.zerbe, PresidentandCEOofIntelGenx. WearepleasedtobeworkingwithTetratobringthismuch-neededcannabinoid producttonorthamericanpatientssufferingfromanorexiaandcancerchemotherapy-relatedpain. WearepleasedtoannouncethesigningofthedefinitiveagreementwithIntelGenxandlookforwardtoworkingveryhardwiththemtobringthismuch-needed producttopatientssufferingfromcancerpain, saidandrerancourt,ceooftetra. TheexecutionofthisagreementisjustthebeginningforTetraaswelook forward to aggressively concluding future agreements as we build a leading bio-pharmaceutical organization focused on developing medicinal cannabis as pharmaceuticaldrugs. BackgroundInformation

4 TherearemanyclinicalproblemsassociatedwiththeuseofcurrentlyavailableformofDronabinolinpatientswithanorexiaandcancerchemotherapy-relatedpain. It has been demonstrated that psychoactive drugs exert their euphoria, and other psychoactive effects, when the blood levels of the drug rapidly increase. The pharmacokinetic profile of tetrahydrocannabinol ( THC ) and its metabolite increases the abuse potential of cannabinoids like Dronabinol. The significant advantage of an oral mucoadhesive tablet based on IntelGenx proprietary AdVersa controlled-release technology is that it can be adjusted to achieve a predetermineddrugreleasepatternbyincreasingtheresidencetime,promotingintimatecontactwiththemucosaltissueandincreasingthebioadhesiveproperties ofthedosageform.itisbelievedthat,bydeployingthistechnologyinthecontrolled-releaseofthc,alongertimereleaseofthedrugwillbeachievedand, thereby,arapidincreaseinthebloodwillbeavoided.therewillalsopotentiallybeimprovedbioavailabilityandreducedgastro-intestinalsideeffects,makinga sustained-releasethcproductapromisingalternativeinthebattleforthereductionofopioidsinpatientswithchronicpain. AboutTetraBioPharma Tetra Bio Pharma is a multi-subsidiary publicly traded company (CSE: TBP) (OTCPINK: GRPOF) engaged in the development of Bio Pharmaceuticals and NaturalHealthProductscontainingCannabisandothermedicinalplantbasedelements. TetraBioPharmaisfocusedoncombiningthetraditionalmethodsofmedicinalcannabisusewiththesupportingscientificvalidationandsafetydatarequiredfor inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: AboutIntelGenx IntelGenxisaleadingoraldrugdeliverycompanyprimarilyfocusedonthedevelopmentandmanufacturingofinnovativepharmaceuticaloralfilmsbasedonits proprietaryversafilm technologyplatform.establishedin2003,themontreal-basedcompanyislistedonthetsx-vandotc-qx. IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinicalmonitoring,ipandregulatoryservices.intelgenxstate-of-theartmanufacturingfacility,establishedfortheversafilm technologyplatform,supportslabscale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: Forward-LookingStatements Thisdocumentmaycontainforward-lookinginformationaboutIntelGenx'operatingresultsandbusinessprospectsthatinvolvesubstantialrisksanduncertainties. Statementsthatarenotpurelyhistoricalareforward-lookingstatementswithinthemeaningofSection21EoftheSecuritiesExchangeActof1934,asamended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates,""intends,""plans,""believes,""seeks,""estimates,""could,""would,"andsimilarexpressions.allforward-lookingstatementsareexpresslyqualified intheirentiretybythiscautionarystatement.becausetheseforward-lookingstatementsaresubjecttoanumberofrisksanduncertainties,intelgenx'actualresults coulddiffermateriallyfromthoseexpressedorimpliedbytheseforward-lookingstatements.factorsthatcouldcauseorcontributetosuchdifferencesinclude,but arenotlimitedto,thosediscussedundertheheading"riskfactors"inintelgenx'annualreportonform10-k,filedwiththeunitedstatessecuritiesandexchange Commissionandavailableatwww.sec.gov,andalsofiledwithCanadiansecuritiesregulatoryauthoritiesandwww.sedar.com.IntelGenxassumesnoobligationto updateanysuchforward-lookingstatements.

5 NeitherTSXVentureExchangenoritsRegulationServicesProvider(asthattermisdefinedinthepoliciesoftheTSXVentureExchange),northeOTCQXaccepts responsibilityfortheadequacyoraccuracyofthisrelease. Source:IntelGenxTechnologiesCorp. Formoreinformation,pleasecontact: StephenKilmer InvestorRelations (514) ext232 AndreGodin,CPA,CA ExecutiveVice-PresidentandCFO (514) ext203

FORM8-K HILLENBRAND,INC.

FORM8-K HILLENBRAND,INC. UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): December18,2015